Cytori Therapeutics (CYTX) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities rebound to close higher as surging Treasury yields recede
- Fed’s Jefferson sees no urgency for another rate increase
- Oil jumps 4% on reports China halts fuel exports, US troops head to Middle East
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
Roth Capital Cuts Price Target on Cytori Therapeutics (CYTX) Following 3Q15
November 9, 2015 8:40 AM ESTRoth Capital maintained a Buy rating on Cytori Therapeutics, Inc. (NASDAQ: CYTX), and cut the price target of $2.50 (from $4.00), following the company's 3Q15 earnings report. CYTX reported EPS of $0.01 compared with the consensus estimate of ($0.06).
Analyst Joseph Pantginis commented, "With four potential approval... More
